Skip to main content

BrightSpring Health Services Announces Onco360® Has Been Selected as a Partner for Several New Drugs

Written by Customer Service on . Posted in Public Companies.

LOUISVILLE, Ky., Nov. 26, 2024 (GLOBE NEWSWIRE) — BrightSpring Health Services (“BrightSpring” or “BrightSpring Health Services”) (NASDAQ: BTSG) is proud of its specialty pharmacy partner, Onco360®, for being selected as the national pharmacy partner for multiple medications approved to treat advanced cancers and blood disease.

“Our partner Onco360 is rapidly bringing innovative medicines and treatments to market to help improve the lives of patients living with once untreatable, rare diseases,” said BrightSpring’s President and CEO, Jon Rosseau. “We are proud of their work to distribute breakthrough therapies and treatments to life-threatening diseases, expanding available care options, and extending the lives of many patients facing rare cancers and blood diseases.”

Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner for the following medications:

  • ITOVEBI™ is approved to treat certain types of locally advanced or metastatic breast cancer.
  • Rytelo™ is approved for the treatment of adult patients with myelodysplastic syndromes, a group of cancers that occur when the bone marrow produces immature blood cells.
  • Voranigo® is approved for the treatment of adults and pediatric patients 12 years and older with certain types of brain tumors called astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation.
  • PIASKY® is approved to treat adults and pediatric patients 13-years and older that have paroxysmal nocturnal hemoglobinuria, a life-threatening blood disorder that causes the destruction of red blood cells.
  • Tevimbra® is approved for the treatment of adult patients with metastatic esophageal cell carcinoma after prior systemic chemotherapy.
  • LAZCLUZE™ is approved as a first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer.
  • Revuforj® is the first and only menin inhibitor approved for the treatment of relapsed or refractory acute leukemias with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients.
  • Vyloy® is currently the first and only approved monoclonal antibody specifically designed to target gastric tumor cells that express the biomarker claudin (CLDN) 18.2.

About BrightSpring Health Services: 
BrightSpring Health Services provides complementary and integrated home- and community-based pharmacy and health solutions for complex populations in need of specialized and/or chronic care.  Through the Company’s service lines, including pharmacy, home health care and primary care, and rehabilitation and behavioral health, we provide comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients and patients daily. 

About Onco360 Oncology Pharmacy:
Onco360 is the nation’s largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Specialty Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Onco360.com.

Media Contact
Leigh White
Leigh.white@brightspringhealth.com
502.630.7412

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.